Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
about
Ponatinib in refractory Philadelphia chromosome-positive leukemias.Drug Therapy in the Progressed CML Patient with multi-TKI FailurePharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasBosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisNovel targeted therapies for eosinophil-associated diseases and allergyNilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitorsTreatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experienceSuboptimal responses in chronic myeloid leukemia: implications and management strategiesChronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureEarly responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesTreatment of chronic myeloid leukemia when imatinib fails.Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.Selection of therapy: rational decisions based on molecular events.Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.Treatment options for chronic myeloid leukemia.Treatments for chronic myeloid leukemia: a qualitative systematic review.Surrogate end points for long-term outcomes in chronic myeloid leukemia.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib.Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia.Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibNilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty.Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance.
P2860
Q27851967-C01C51D4-1CFA-437F-9AC2-C49A418B8F91Q28085353-F7A5ADF4-EA15-4573-923A-4DFAC8E2C805Q33403826-96290C74-6F5F-4603-B43C-1C142FCEC7BFQ33406299-C3C91F66-7B7E-4AE6-BFCF-58D80151519AQ33408546-392A2EC4-4253-413A-BBB8-D1422EE3B477Q33411250-CB9CC474-E255-4D5B-8C11-65FFE7B48E5AQ33414487-9D409931-D937-44A6-A993-FF2519737698Q33434675-8830D851-36F9-4644-8CEE-87A0C97CCED7Q34272887-7A923812-90A2-4EE0-9297-1990A9D384F0Q34444620-8819A9DE-E5FE-43B8-8D31-15F81B923E46Q34639998-CD25BB03-6C74-496F-A193-43957EA8820AQ34774289-09D5EEC5-80B9-4D66-9FEB-9B5A578D1899Q35051937-A98BBFE0-0E95-4EC2-A8F7-A0051377BC7DQ35595870-49354EF5-4B35-4922-B6A1-926E17CC764BQ35899653-FAC9E338-297E-46BE-BF2E-6EB7526F3A55Q36144079-849CFD6E-4651-459B-BAAF-48B503066272Q36364850-773875BE-0C6C-423D-9F78-746D306AC88EQ37026032-4AFE25D4-3FAF-424E-94FE-7AF2B9CE38D5Q37027759-0A020D92-5356-47F7-B643-EDA13A2052CAQ37095355-5CBA8CB8-41B3-4D9B-86D3-C2E9F05C854BQ37827875-E3ADF2DB-9B15-4129-96B1-C093AD8B1712Q37918304-115D3C5B-8FDB-4D2F-9977-8A218C2D2D69Q37952910-241AE302-66E0-4883-B7FA-30BDA929EDF1Q37965564-7E251EBD-D4D5-41F8-A317-B1B05029FF5EQ37994805-50E7D05F-625F-4785-B5A9-E7CED3A6C290Q38037079-9EAE9A01-782F-4908-8F57-ACC6353FC429Q38079249-43E31097-7FE1-4974-AB85-F77A5A65DC2AQ38139571-80007842-3FA2-421A-94F0-C9600B498729Q38216677-7A65513F-EB62-4A05-91B9-8107340FFF1BQ38478174-B9EEE566-E3AE-4A09-95C6-B67B61671078Q38764223-480AC952-D38A-4FE9-8E3A-D039D0A0D0AAQ39308709-5D25512B-081F-4931-9840-5F130764A6CEQ39779762-21CB6339-6828-4E91-BE29-EEB76AC0C9A6Q41304682-29331828-C493-4F4B-90AB-9B213760D347Q42796997-E16FD5DA-B155-4F68-8B3E-44EED552DB03Q43841175-38B604F3-062D-4EC7-B353-348310989691Q47838580-485D6093-8918-4E43-A869-BAA82E7E3519Q49979322-80E419FD-A0D0-4A97-8BE3-D7BAB37A0ACBQ54310937-A9AA301A-B22B-4F14-BF22-2333C78A8CBF
P2860
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Nilotinib is active in chronic ...... matinib and dasatinib therapy.
@ast
Nilotinib is active in chronic ...... matinib and dasatinib therapy.
@en
Nilotinib is active in chronic ...... matinib and dasatinib therapy.
@nl
type
label
Nilotinib is active in chronic ...... matinib and dasatinib therapy.
@ast
Nilotinib is active in chronic ...... matinib and dasatinib therapy.
@en
Nilotinib is active in chronic ...... matinib and dasatinib therapy.
@nl
prefLabel
Nilotinib is active in chronic ...... matinib and dasatinib therapy.
@ast
Nilotinib is active in chronic ...... matinib and dasatinib therapy.
@en
Nilotinib is active in chronic ...... matinib and dasatinib therapy.
@nl
P2093
P2860
P356
P1433
P1476
Nilotinib is active in chronic ...... imatinib and dasatinib therapy
@en
P2093
H M Kantarjian
M Baccarani
P2860
P2888
P304
P356
10.1038/LEU.2010.110
P577
2010-06-03T00:00:00Z
P5875
P6179
1016924943